Response to the Commentary on Is posttransplant lenalidomide the standardofcare after an autotransplant for plasma cell myeloma

Response to the Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma”

18:17 EST 6 Mar 2019 | Nature Publishing

More From BioPortfolio on "Response to the Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma”"